免疫检查点抑制剂在肾细胞癌治疗中的应用。
Immune Checkpoint Inhibitors in the Treatment of Renal Cell Carcinoma.
机构信息
Division of Hematology Oncology, Department of Internal Medicine, School of Medicine, University of California, Davis, Sacramento, CA.
Department of Internal Medicine, School of Medicine, University of California, Davis, Sacramento, CA.
出版信息
Semin Nephrol. 2020 Jan;40(1):76-85. doi: 10.1016/j.semnephrol.2019.12.009.
Abstract
Immune checkpoint inhibitors have quickly become a critical component to the management of advanced renal cell carcinoma. These therapies have been approved for patients who are treatment-naive and who have progressed on antiangiogenesis agents. Combinations of immune checkpoint inhibitors with antiangiogenesis agents show significant response rates and prolong survival. Adverse events associated with the use of checkpoint inhibition present unique challenges in the management of patients, and careful considerations are needed when checkpoint inhibitors are combined with antiangiogenesis agents. Nevertheless, the improvement in overall survival associated with these agents indicates that they will remain a vital component of kidney cancer treatment.
摘要
免疫检查点抑制剂已迅速成为晚期肾细胞癌治疗的重要组成部分。这些治疗方法已被批准用于治疗初治和抗血管生成药物进展的患者。免疫检查点抑制剂与抗血管生成药物联合使用显示出显著的反应率和延长的生存时间。使用检查点抑制相关的不良反应在患者管理方面带来了独特的挑战，当检查点抑制剂与抗血管生成药物联合使用时需要谨慎考虑。然而，这些药物带来的总体生存改善表明它们将仍然是肾癌治疗的重要组成部分。
相似文献
1
Immune Checkpoint Inhibitors in the Treatment of Renal Cell Carcinoma.免疫检查点抑制剂在肾细胞癌治疗中的应用。
Semin Nephrol. 2020 Jan;40(1):76-85. doi: 10.1016/j.semnephrol.2019.12.009.
2
Magnetic resonance imaging criteria of immune checkpoint inhibitor-induced hypophysitis.免疫检查点抑制剂诱导的垂体炎的磁共振成像标准。
Curr Probl Cancer. 2021 Feb;45(1):100644. doi: 10.1016/j.currproblcancer.2020.100644. Epub 2020 Aug 29.
3
Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis.免疫检查点抑制剂治疗引起的垂体炎患者的继发性肾上腺功能不全的恢复。
J Immunother Cancer. 2019 Sep 12;7(1):248. doi: 10.1186/s40425-019-0729-3.
4
Pembrolizumab plus axitinib combination and the paradigm change in the treatment of advanced renal cell carcinoma.帕博利珠单抗联合阿昔替尼治疗晚期肾细胞癌及治疗模式的改变
Future Oncol. 2021 Jan;17(3):241-254. doi: 10.2217/fon-2020-0079. Epub 2020 Oct 5.
5
Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma.更新的欧洲泌尿外科学会肾癌指南：免疫检查点抑制是转移性透明细胞肾细胞癌一线治疗的新支柱。
Eur Urol. 2019 Aug;76(2):151-156. doi: 10.1016/j.eururo.2019.05.022.
6
Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma.更新的欧洲泌尿外科学会肾癌指南：纳武利尤单抗联合卡博替尼加入免疫检查点抑制联合治疗用于治疗初治转移性透明细胞肾细胞癌。
Eur Urol. 2021 Mar;79(3):339-342. doi: 10.1016/j.eururo.2020.12.005. Epub 2020 Dec 24.
7
A real-world data of Immune checkpoint inhibitors in solid tumors from India.印度实体瘤免疫检查点抑制剂的真实世界数据。
Cancer Med. 2021 Mar;10(5):1525-1534. doi: 10.1002/cam4.3617. Epub 2021 Feb 16.
8
Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study.阿昔替尼个体化方案治疗接受检查点抑制剂治疗后的转移性肾细胞癌患者：一项多中心、单臂、2 期研究。
Lancet Oncol. 2019 Oct;20(10):1386-1394. doi: 10.1016/S1470-2045(19)30513-3. Epub 2019 Aug 16.
9
Nivolumab and ipilimumab immunotherapy for hemodialysis patients with advanced renal cell carcinoma.纳武利尤单抗和伊匹单抗免疫治疗晚期肾细胞癌血液透析患者。
Curr Oncol. 2020 Aug;27(4):225-228. doi: 10.3747/co.27.6439. Epub 2020 Aug 1.
10
Avelumab and axitinib combination therapy for the treatment of advanced renal cell carcinoma.avelumab 与阿昔替尼联合治疗晚期肾细胞癌。
Future Oncol. 2020 Dec;16(36):3021-3034. doi: 10.2217/fon-2020-0586. Epub 2020 Aug 28.
引用本文的文献
1
Advances in immunotherapy and targeted therapy for advanced clear-cell renal cell carcinoma: current strategies and future directions.晚期透明细胞肾细胞癌免疫治疗和靶向治疗的进展：当前策略与未来方向
Front Immunol. 2025 Jul 3;16:1582887. doi: 10.3389/fimmu.2025.1582887. eCollection 2025.
2
Second-Line Systemic Therapies in Metastatic Renal Cell Carcinoma: Current Insights and Future Directions.转移性肾细胞癌的二线全身治疗：当前见解与未来方向
J Cancer Immunol (Wilmington). 2025;7(2):81-94. doi: 10.33696/cancerimmunol.7.107.
3
Tivozanib Monotherapy in the Frontline Setting for Patients with Metastatic Renal Cell Carcinoma and Favorable Prognosis.替沃扎尼单药一线治疗转移性肾细胞癌且预后良好的患者
Curr Oncol Rep. 2024 Dec;26(12):1639-1650. doi: 10.1007/s11912-024-01613-7. Epub 2024 Nov 20.
4
Research progress of MUC1 in genitourinary cancers.MUC1 在泌尿生殖系统癌症中的研究进展。
Cell Mol Biol Lett. 2024 Nov 3;29(1):135. doi: 10.1186/s11658-024-00654-x.
5
Immunotherapy of Clear-Cell Renal-Cell Carcinoma.透明细胞肾细胞癌的免疫疗法
Cancers (Basel). 2024 May 31;16(11):2092. doi: 10.3390/cancers16112092.
6
15 years of patient-reported outcomes in clinical trials leading to GU cancer drug approvals: a systematic review on the quality of data reporting and analysis.导致泌尿生殖系统癌症药物获批的临床试验中15年患者报告结局：关于数据报告与分析质量的系统评价
EClinicalMedicine. 2024 Jan 5;68:102413. doi: 10.1016/j.eclinm.2023.102413. eCollection 2024 Feb.
7
Butyrate facilitates immune clearance of colorectal cancer cells by suppressing STAT1-mediated PD-L1 expression.丁酸盐通过抑制 STAT1 介导的 PD-L1 表达促进结直肠癌细胞的免疫清除。
Clinics (Sao Paulo). 2023 Nov 4;78:100303. doi: 10.1016/j.clinsp.2023.100303. eCollection 2023.
8
Rosmarinic acid in combination with ginsenoside Rg1 suppresses colon cancer metastasis via co-inhition of COX-2 and PD1/PD-L1 signaling axis.迷迭香酸与人参皂苷Rg1联合通过共同抑制COX-2和PD1/PD-L1信号轴抑制结肠癌转移。
Acta Pharmacol Sin. 2024 Jan;45(1):193-208. doi: 10.1038/s41401-023-01158-8. Epub 2023 Sep 25.
9
Patients with melanoma treated with immune checkpoint inhibitors who had non-thyroid endocrine and skin immune-related adverse events have better prognosis: A systematic review and meta-analysis.接受免疫检查点抑制剂治疗且出现非甲状腺内分泌和皮肤免疫相关不良事件的黑色素瘤患者预后较好：一项系统评价和荟萃分析。
Front Oncol. 2022 Sep 14;12:976224. doi: 10.3389/fonc.2022.976224. eCollection 2022.
10
Kinase activity profiling in renal cell carcinoma, benign renal tissue and in response to four different tyrosine kinase inhibitors.肾细胞癌、良性肾组织中的激酶活性分析，以及对四种不同酪氨酸激酶抑制剂的反应。
Oncotarget. 2022 Aug 4;13:970-981. doi: 10.18632/oncotarget.28257. eCollection 2022.
本文引用的文献
1
A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and Pembrolizumab Combination Therapy in Patients with Advanced Renal Cell Carcinoma.帕唑帕尼和帕博利珠单抗联合治疗晚期肾细胞癌患者的 I/II 期研究评估安全性和疗效。
Clin Genitourin Cancer. 2021 Oct;19(5):434-446. doi: 10.1016/j.clgc.2021.04.007. Epub 2021 Apr 20.
2
Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody.分析接受程序性死亡蛋白 1 或程序性死亡配体 1 抗体治疗的患者不良事件与结局之间的关联。
J Clin Oncol. 2019 Oct 20;37(30):2730-2737. doi: 10.1200/JCO.19.00318. Epub 2019 May 22.
3
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.阿替利珠单抗联合贝伐珠单抗对比舒尼替尼用于既往未接受治疗的转移性肾细胞癌患者（IMmotion151）：一项多中心、开放标签、III 期、随机对照临床试验。
Lancet. 2019 Jun 15;393(10189):2404-2415. doi: 10.1016/S0140-6736(19)30723-8. Epub 2019 May 9.
4
The nephrotoxicity of new immunotherapies.新型免疫疗法的肾毒性。
Expert Rev Clin Pharmacol. 2019 Jun;12(6):513-521. doi: 10.1080/17512433.2019.1613888. Epub 2019 May 8.
5
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.阿维鲁单抗联合阿昔替尼与舒尼替尼治疗晚期肾细胞癌。
N Engl J Med. 2019 Mar 21;380(12):1103-1115. doi: 10.1056/NEJMoa1816047. Epub 2019 Feb 16.
6
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.派姆单抗联合阿昔替尼对比舒尼替尼用于晚期肾细胞癌。
N Engl J Med. 2019 Mar 21;380(12):1116-1127. doi: 10.1056/NEJMoa1816714. Epub 2019 Feb 16.
7
Renal toxicities associated with pembrolizumab.与帕博利珠单抗相关的肾毒性。
Clin Kidney J. 2019 Feb;12(1):81-88. doi: 10.1093/ckj/sfy100. Epub 2018 Nov 9.
8
Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study.纳武利尤单抗联合舒尼替尼或帕唑帕尼治疗晚期或转移性肾细胞癌的安全性和有效性：CheckMate 016 研究。
J Immunother Cancer. 2018 Oct 22;6(1):109. doi: 10.1186/s40425-018-0420-0.
9
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.阿替利珠单抗单药或联合贝伐珠单抗与舒尼替尼治疗肾细胞癌的临床活性和分子相关性。
Nat Med. 2018 Jun;24(6):749-757. doi: 10.1038/s41591-018-0053-3. Epub 2018 Jun 4.
10
The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma.PD-1/PD-L1 抑制剂在转移性非透明细胞肾细胞癌中的临床活性。
Cancer Immunol Res. 2018 Jul;6(7):758-765. doi: 10.1158/2326-6066.CIR-17-0475. Epub 2018 May 10.
Zotero 插件